Business
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the World Health Organization (WHO) has granted the international nonproprietary (generic) name (INN) of “izicopan” to the Company for its orally available C5aR inhibitor, formerly known as INF904, in accordance with the WHO's Procedure for the Selection of Recommended International Nonpropriet
About this update from Inflarx N.v.
[{"type":"image","alt":"InflaRx N.V.","displaySize":"","headline":null,"caption":"InflaRx N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/105c0226a90fc647941f68c2de55213a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lqiU0gFIS0tiIdhYPTjZSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/105c0226a90fc647941f68c2de55213a","width":300,"height":157}},"lazy":false},{"type":"text","content":"JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the World Health Organization (WHO) has granted the international nonproprietary (generic) name (INN) of “izicopan” to the Company for its orally available C5aR inhibitor, formerly known as INF904, in accordance with the WHO's Procedure for the Selection of Recommended International Nonproprietary Names (INN) for Pharmaceutical Substances. In the next step of this process, the name “izicopan” will be published in the recommended list of INNs.","length":655,"tagName":"p"},{"type":"text","content":"Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “InflaRx welcomes the granting of izicopan as the INN for INF904. We believe the promising clinical data recently reported in hidradenitis suppurativa and chronic spontaneous urticaria indicate the tremendous potential izicopan has, as a best-in-class oral agent with a novel mechanism of action, to address significant unmet need in both diseases and also to address sizable commercial markets in additional inflammatory conditions.”","length":519,"tagName":"p"},{"type":"text","content":"About izicopan (INF904)Izicopan (INF904) is an orally administered, small molecule inhibitor of the C5a receptor Ca5R1 that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in human studies. Further, in contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that izicopan has minimal inhibition of the cytochrome P450 3A4/5 (CYP3A4/5) enzymes, which play an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Reported results from a first-in-human study demo...